Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.

Wai DC, Szyszka TN, Campbell AE, Kwong C, Wilkinson-White LE, Silva APG, Low JKK, Kwan AH, Gamsjaeger R, Chalmers JN, Patrick WM, Lu B, Vakoc CR, Blobel G, Mackay JP.

J Biol Chem. 2018 Mar 22. pii: jbc.RA117.000678. doi: 10.1074/jbc.RA117.000678. [Epub ahead of print]

2.

LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia.

Tarumoto Y, Lu B, Somerville TDD, Huang YH, Milazzo JP, Wu XS, Klingbeil O, El Demerdash O, Shi J, Vakoc CR.

Mol Cell. 2018 Mar 15;69(6):1017-1027.e6. doi: 10.1016/j.molcel.2018.02.011. Epub 2018 Mar 8.

PMID:
29526696
3.

The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.

Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, Dancsok AR, Hatzi K, Chen CC, Tschaharganeh DF, Chandwani R, Tasdemir N, Jones KB, Capecchi MR, Vakoc CR, Schultz N, Ladanyi M, Nielsen TO, Lowe SW.

Cancer Cell. 2018 Mar 12;33(3):527-541.e8. doi: 10.1016/j.ccell.2018.01.018. Epub 2018 Mar 1.

PMID:
29502955
4.

Enhancer dysfunction in leukemia.

Bhagwat AS, Lu B, Vakoc CR.

Blood. 2018 Apr 19;131(16):1795-1804. doi: 10.1182/blood-2017-11-737379. Epub 2018 Feb 9. Review.

PMID:
29439951
5.

A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia.

Xu Y, Milazzo JP, Somerville TDD, Tarumoto Y, Huang YH, Ostrander EL, Wilkinson JE, Challen GA, Vakoc CR.

Cancer Cell. 2018 Jan 8;33(1):13-28.e8. doi: 10.1016/j.ccell.2017.12.002.

PMID:
29316427
6.

Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T.

Nature. 2017 Dec 7;552(7683):126-131. doi: 10.1038/nature24678. Epub 2017 Nov 27.

PMID:
29186125
7.

Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.

Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, Filipescu D, Valle-Garcia D, Darvishian F, Roe JS, Davies MA, Vakoc CR, Hernando E, Bernstein E.

Mol Cell. 2017 Nov 16;68(4):731-744.e9. doi: 10.1016/j.molcel.2017.11.004.

PMID:
29149598
8.

Soils and Seeds That Initiate Pancreatic Cancer Metastasis.

Vakoc CR, Tuveson DA.

Cancer Discov. 2017 Oct;7(10):1067-1068. doi: 10.1158/2159-8290.CD-17-0887.

PMID:
28974531
9.

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR.

Cell. 2017 Aug 24;170(5):875-888.e20. doi: 10.1016/j.cell.2017.07.007. Epub 2017 Jul 27.

PMID:
28757253
10.

Single-minded CRISPR screening.

Lanning BR, Vakoc CR.

Nat Biotechnol. 2017 Apr 11;35(4):339-340. doi: 10.1038/nbt.3849. No abstract available.

PMID:
28398325
11.

Untangling the genetics from the epigenetics in pancreatic cancer metastasis.

Vakoc CR, Tuveson DA.

Nat Genet. 2017 Feb 24;49(3):323-324. doi: 10.1038/ng.3798.

PMID:
28232730
12.

Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.

Ipsaro JJ, Shen C, Arai E, Xu Y, Kinney JB, Joshua-Tor L, Vakoc CR, Shi J.

PLoS One. 2017 Feb 23;12(2):e0172177. doi: 10.1371/journal.pone.0172177. eCollection 2017.

13.

Targeting Cancer Cells with BET Bromodomain Inhibitors.

Xu Y, Vakoc CR.

Cold Spring Harb Perspect Med. 2017 Jul 5;7(7). pii: a026674. doi: 10.1101/cshperspect.a026674. Review.

14.

The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia.

Roe JS, Vakoc CR.

Cold Spring Harb Symp Quant Biol. 2016;81:61-66. doi: 10.1101/sqb.2016.81.031039. Epub 2017 Feb 7. Review.

15.

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.

Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, Shen C, Rigoutsos I, King MP, Cotney JL, Arnold JJ, Sharma SD, Martinez-Outschoorn UE, Vakoc CR, Chodosh LA, Thompson JE, Bradner JE, Cameron CE, Shadel GS, Eischen CM, McMahon SB.

Oncotarget. 2016 Nov 8;7(45):72395-72414. doi: 10.18632/oncotarget.11718.

16.

A Biomarker Harvest from One Thousand Cancer Cell Lines.

Huang YH, Vakoc CR.

Cell. 2016 Jul 28;166(3):536-537. doi: 10.1016/j.cell.2016.07.010.

17.

Modeling the Epigenetic Chain Reaction Downstream of DNMT3A(R882H).

Somerville TDD, Vakoc CR.

Cancer Cell. 2016 Jul 11;30(1):9-10. doi: 10.1016/j.ccell.2016.06.018.

18.

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.

Hohmann AF, Martin LJ, Minder JL, Roe JS, Shi J, Steurer S, Bader G, McConnell D, Pearson M, Gerstberger T, Gottschamel T, Thompson D, Suzuki Y, Koegl M, Vakoc CR.

Nat Chem Biol. 2016 Sep;12(9):672-9. doi: 10.1038/nchembio.2115. Epub 2016 Jul 4.

19.

Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4.

Zhang Q, Zeng L, Shen C, Ju Y, Konuma T, Zhao C, Vakoc CR, Zhou MM.

Structure. 2016 Jul 6;24(7):1201-8. doi: 10.1016/j.str.2016.04.019. Epub 2016 Jun 9.

20.

BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.

Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW.

Cancer Discov. 2016 Jun;6(6):612-29. doi: 10.1158/2159-8290.CD-16-0217. Epub 2016 Apr 20.

21.

BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements.

Bhagwat AS, Roe JS, Mok BYL, Hohmann AF, Shi J, Vakoc CR.

Cell Rep. 2016 Apr 19;15(3):519-530. doi: 10.1016/j.celrep.2016.03.054. Epub 2016 Apr 7.

22.

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.

Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D.

J Med Chem. 2016 May 26;59(10):4462-75. doi: 10.1021/acs.jmedchem.5b01865. Epub 2016 Mar 10.

23.

Targeting Transcription Factors in Cancer.

Bhagwat AS, Vakoc CR.

Trends Cancer. 2015 Sep 1;1(1):53-65.

24.

NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.

Shen C, Ipsaro JJ, Shi J, Milazzo JP, Wang E, Roe JS, Suzuki Y, Pappin DJ, Joshua-Tor L, Vakoc CR.

Mol Cell. 2015 Dec 17;60(6):847-59. doi: 10.1016/j.molcel.2015.10.033. Epub 2015 Nov 25.

25.

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW.

Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.

26.

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J.

Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14.

27.

BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.

Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR.

Mol Cell. 2015 Jun 18;58(6):1028-39. doi: 10.1016/j.molcel.2015.04.011. Epub 2015 May 14.

28.

Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.

Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR.

Nat Biotechnol. 2015 Jun;33(6):661-7. doi: 10.1038/nbt.3235. Epub 2015 May 11.

29.

The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer.

Wang E, Kawaoka S, Roe JS, Shi J, Hohmann AF, Xu Y, Bhagwat AS, Suzuki Y, Kinney JB, Vakoc CR.

Elife. 2015 Apr 28;4:e06377. doi: 10.7554/eLife.06377.

30.

TGF-β/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis.

Yu JR, Tai Y, Jin Y, Hammell MC, Wilkinson JE, Roe JS, Vakoc CR, Van Aelst L.

Genes Dev. 2015 Feb 1;29(3):250-61. doi: 10.1101/gad.248963.114.

31.

Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.

Shen C, Vakoc CR.

Curr Opin Oncol. 2015 Jan;27(1):57-63. doi: 10.1097/CCO.0000000000000151. Review.

32.

Brd4 is on the move during inflammation.

Xu Y, Vakoc CR.

Trends Cell Biol. 2014 Nov;24(11):615-6. doi: 10.1016/j.tcb.2014.09.005. Epub 2014 Oct 3.

33.

A rationale to target the SWI/SNF complex for cancer therapy.

Hohmann AF, Vakoc CR.

Trends Genet. 2014 Aug;30(8):356-63. doi: 10.1016/j.tig.2014.05.001. Epub 2014 Jun 3. Review.

34.

Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5.

Mazurek A, Park Y, Miething C, Wilkinson JE, Gillis J, Lowe SW, Vakoc CR, Stillman B.

Cell Rep. 2014 Jun 26;7(6):1887-99. doi: 10.1016/j.celrep.2014.05.019. Epub 2014 Jun 5.

35.

The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

Shi J, Vakoc CR.

Mol Cell. 2014 Jun 5;54(5):728-36. doi: 10.1016/j.molcel.2014.05.016. Review.

36.

A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response.

Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, Blanco A, Chen S, Stützer A, Armache KJ, Simon MD, Xu C, Ali M, Murn J, Prisic S, Kutateladze TG, Vakoc CR, Min J, Kingston RE, Fischle W, Warren ST, Page DC, Shi Y.

Cell. 2014 May 8;157(4):869-81. doi: 10.1016/j.cell.2014.03.040.

37.

MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.

Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW.

Cancer Cell. 2014 May 12;25(5):652-65. doi: 10.1016/j.ccr.2014.03.016. Epub 2014 May 1.

38.

A new bump in the epigenetic landscape.

Bhagwat AS, Vakoc CR.

Mol Cell. 2014 Mar 20;53(6):857-8. doi: 10.1016/j.molcel.2014.03.001.

39.

C/EBPα: critical at the origin of leukemic transformation.

Roe JS, Vakoc CR.

J Exp Med. 2014 Jan 13;211(1):1-4. doi: 10.1084/jem.20132530. Epub 2014 Jan 6. Review.

40.

Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.

Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, Minder JL, Mercan F, Wang E, Eckersley-Maslin MA, Campbell AE, Kawaoka S, Shareef S, Zhu Z, Kendall J, Muhar M, Haslinger C, Yu M, Roeder RG, Wigler MH, Blobel GA, Zuber J, Spector DL, Young RA, Vakoc CR.

Genes Dev. 2013 Dec 15;27(24):2648-62. doi: 10.1101/gad.232710.113. Epub 2013 Nov 27.

41.

Oncogene interference through targeting of chromatin regulators.

Roe JS, Vakoc CR.

Cell Cycle. 2013 May 15;12(10):1475-6. doi: 10.4161/cc.24748. Epub 2013 Apr 22. No abstract available.

42.

Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA.

Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.

43.

Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.

Wang E, Kawaoka S, Yu M, Shi J, Ni T, Yang W, Zhu J, Roeder RG, Vakoc CR.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3901-6. doi: 10.1073/pnas.1301045110. Epub 2013 Feb 14.

44.

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P.

Oncotarget. 2012 Dec;3(12):1588-99.

45.

WRAD: enabler of the SET1-family of H3K4 methyltransferases.

Ernst P, Vakoc CR.

Brief Funct Genomics. 2012 May;11(3):217-26. doi: 10.1093/bfgp/els017. Epub 2012 May 30. Review.

46.

The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.

Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, Lowe SW, Vakoc CR.

Oncogene. 2013 Feb 14;32(7):930-8. doi: 10.1038/onc.2012.110. Epub 2012 Apr 2.

47.

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.

Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1.

48.

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW.

Genes Dev. 2011 Aug 1;25(15):1628-40. doi: 10.1101/gad.17269211. Erratum in: Genes Dev. 2011 Sep 15;25(18):1997. Fellman, Christof [corrected to Fellmann, Christof].

49.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR.

Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334.

50.

PAF is in the cabal of MLL1-interacting proteins that promote leukemia.

Speck NA, Vakoc CR.

Cancer Cell. 2010 Jun 15;17(6):531-2. doi: 10.1016/j.ccr.2010.05.019.

Supplemental Content

Loading ...
Support Center